European Pharmaceutical Review

FEBRUARY 20, 2024

percent between 2022 and 2029. The rising productivity of cell lines has improved the performance of upstream processing with low cost and high process reproducibility, the report explained. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78

Process Improvement 98

Process Improvement Biosimilars Drug Development 98

European Pharmaceutical Review

MAY 29, 2023

Recently, the European Medicines Agency (EMA) took the lead in pushing for process improvements using technologies already established in other manufacturing sectors. Despite this, only 13 nanomedicines had been approved by the US Food and Drug Administration (FDA) before 2015. Yet in 2021, 100 nanomedicines had been marketed.

Process Improvement 95

Process Improvement Packaging Vaccines Drug Development 95

Express Pharma

JULY 10, 2024

She also suggests, “India can foster collaboration between the IT and the biopharma companies through government or private initiated collaborative channels – these can help facilitate discussions around latest technological advancements available that could help in overcoming challenges in biopharma drug development and advancement.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96